A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
24
01
2022
pubmed:
20
2
2022
medline:
1
6
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
Actinic keratosis (AK) is a chronic skin disease in which clinical and subclinical cutaneous lesions coexist on sun-exposed areas such as the head and neck region and the extremities. The high prevalence of AK means the disease burden is substantial, especially in middle-aged and elderly populations. Evidence indicates that AK may progress into invasive cutaneous squamous cell carcinoma, so the European guidelines recommend treatment of any AK regardless of clinical severity. Given the aging population and therefore the increasing incidence of AK and cutaneous field carcinogenesis, further updates on the long-term efficacy of current therapies and new investigational agents are critical to guide treatment choice. Patients often have difficulty adequately applying topical treatments and coping with adverse local skin reactions, leading to less than optimum treatment adherence. The development of associated local skin symptoms and cosmetic outcomes for the area of interest are also relevant to the choice of an appropriate therapeutic strategy. Treatment is always individually tailored according to the characteristics of both patients and lesions. This review focuses on the therapeutic approaches to AK and illustrates the currently available home-based and physician-managed treatments.
Identifiants
pubmed: 35182332
doi: 10.1007/s40257-022-00674-3
pii: 10.1007/s40257-022-00674-3
pmc: PMC9142445
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-352Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol. 2000;43:138–50. https://doi.org/10.1067/mjd.2000.107497 .
doi: 10.1067/mjd.2000.107497
pubmed: 10863242
Werner RN, Sammain A, Erdmann R, et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18. https://doi.org/10.1111/bjd.12420 .
doi: 10.1111/bjd.12420
pubmed: 23647091
Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006;155:9–22. https://doi.org/10.1111/j.1365-2133.2005.07121.x .
doi: 10.1111/j.1365-2133.2005.07121.x
pubmed: 16792746
Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201–7.
pubmed: 21644496
Ferrandiz C. Update on actinic keratosis in clinical trial experience with imiquimod. Br J Dermatol. 2007;157:32–3. https://doi.org/10.1111/j.1365-2133.2007.08270.x .
doi: 10.1111/j.1365-2133.2007.08270.x
pubmed: 18067629
Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermat. 2018;36:167–76. https://doi.org/10.1016/j.clindermatol.2017.10.008 .
doi: 10.1016/j.clindermatol.2017.10.008
Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Eur J Dermatol. 2017;27:599–608. https://doi.org/10.1684/ejd.2017.3126 .
doi: 10.1684/ejd.2017.3126
pubmed: 29311040
Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol. 2000;115:273–7. https://doi.org/10.1046/j.1523-1747.2000.00048.x .
doi: 10.1046/j.1523-1747.2000.00048.x
pubmed: 10951246
Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross sectional survey. Dermatology. 2008;216:194–9. https://doi.org/10.1159/000112925 .
doi: 10.1159/000112925
pubmed: 18182809
Eder J, Prillinger K, Korn A, et al. Prevalence of actinic keratosis among dermatology outpatients in Austria. Br J Dermatol. 2014;171:1415–21. https://doi.org/10.1111/bjd.13132 .
doi: 10.1111/bjd.13132
pubmed: 24864059
Flohil SC, Van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Investig Dermatol. 2013;133:1971–8. https://doi.org/10.1038/jid.2013.134 .
doi: 10.1038/jid.2013.134
pubmed: 23510990
Ferrándiz C, Plazas MJ, Sabaté M, Palomino R, EPIQA Study Group. Prevalence of actinic keratosis among dermatology outpatients in Spain. Actas Dermosifiliogr 2016;107:674–680. https://doi.org/10.1016/j.ad.2016.05.016
Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatol Treat. 2017;28:431–42. https://doi.org/10.1080/09546634.2016.1254328 .
doi: 10.1080/09546634.2016.1254328
Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–9. https://doi.org/10.1046/j.1365-2133.2000.03541.x .
doi: 10.1046/j.1365-2133.2000.03541.x
pubmed: 10848739
Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738–43. https://doi.org/10.1016/0190-9622(91)70113-g .
doi: 10.1016/0190-9622(91)70113-g
pubmed: 1869646
Schmitz L, Kahl P, Majores M, et al. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30:1303–7. https://doi.org/10.1111/jdv.13626 .
doi: 10.1111/jdv.13626
pubmed: 26955898
Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31:5–7. https://doi.org/10.1111/jdv.14151 .
doi: 10.1111/jdv.14151
pubmed: 28263020
Fernández-Figueras MT, Carrato C, Sáenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991–7. https://doi.org/10.1111/jdv.12848 .
doi: 10.1111/jdv.12848
pubmed: 25428612
Fernández-Figueras MT, Saenz-Sardà X, Vargas P, et al. The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. J Eur Acad Dermatol Venereol. 2018;32:1657–61. https://doi.org/10.1111/jdv.14901 .
doi: 10.1111/jdv.14901
pubmed: 29489051
Philipp-Dormston WG, Battistella M, Boussemart L, et al. Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies. J Dermatolog Treat. 2020;31:576–82. https://doi.org/10.1080/09546634.2019.1679335 .
doi: 10.1080/09546634.2019.1679335
pubmed: 31625770
Willenbrink TJ, Ruiz ES, Cornejo CM, et al. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020;83:709–17. https://doi.org/10.1016/j.jaad.2020.03.126 .
doi: 10.1016/j.jaad.2020.03.126
pubmed: 32387665
Javor S, Gasparini G, Biatta CM, et al. P53 staining index and zonal staining patterns in actinic keratoses. Arch Dermatol Res. 2021;313:275–9. https://doi.org/10.1007/s00403-020-02104-y .
doi: 10.1007/s00403-020-02104-y
pubmed: 32642809
Tang Z, Kang L, Zhang Y, et al. The diagnostic value of in vivo reflectance confocal microscopy in actinic keratosis. Res Technol. 2021;27:80–5. https://doi.org/10.1111/srt.12913 .
doi: 10.1111/srt.12913
Moscarella E, Di Brizzi EV, Casari A, et al. Italian expert consensus paper on the management of patients with actinic keratoses. Dermatol Ther. 2020;33: e13992. https://doi.org/10.1111/dth.13992 .
doi: 10.1111/dth.13992
pubmed: 32648324
De Oliveira ECV, Da Motta VRV, Pantoja PC, et al. Actinic keratosis—review for clinical practice. Int J Dermatol. 2019;58:400–7. https://doi.org/10.1111/ijd.14147 .
doi: 10.1111/ijd.14147
pubmed: 30070357
Hansen JB, Larsson T, Dunkelly-Allen N, et al. Real-World effectiveness and safety of field- and lesion-directed treatments for actinic keratosis. J Drugs Dermatol. 2020;19:756–62. https://doi.org/10.36849/JDD.2020.5123 .
doi: 10.36849/JDD.2020.5123
pubmed: 32804451
Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–41. https://doi.org/10.1111/j.1365-2133.2007.07942.x .
doi: 10.1111/j.1365-2133.2007.07942.x
pubmed: 17501955
Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one of two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265–8. https://doi.org/10.1016/j.jaad.2007.01.047 .
doi: 10.1016/j.jaad.2007.01.047
pubmed: 17512087
Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573–81.
doi: 10.1016/j.jaad.2009.06.020
Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582–90.
doi: 10.1016/j.jaad.2009.07.004
Hanke CW, Swanson N, Bruce S, et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol. 2011;10(2):165–70.
pubmed: 21283921
Dréno B, Cerio R, Dirschka T, et al. A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity. Acta Derm Venereol. 2017;97:1108–13.
doi: 10.2340/00015555-2710
Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935–46. https://doi.org/10.1056/NEJMoa1811850 .
doi: 10.1056/NEJMoa1811850
pubmed: 30855743
Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34–40.
doi: 10.1111/j.1365-2133.2007.08271.x
Askew DA, Mickan SM, Soyer HP, et al. Effectiveness of 5-fluorouracil treatment for actinic keratosis—a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453–63.
doi: 10.1111/j.1365-4632.2009.04045.x
Wu Y, Tang N, Cai L, et al. Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis. Dermatol Ther. 2019;32: e12822. https://doi.org/10.1111/dth.12822 .
doi: 10.1111/dth.12822
pubmed: 30638294
Iglesias-Puzas A, Batalla A, Suh-Oh HJ, et al. 0.5% 5-fluorouracil/10% salicylic acid for the treatment of distal actinic keratoses under daily practice conditions. J Drugs Dermatol. 2019;18:285–8.
pubmed: 30909350
Tan JHY, Hsu AAL. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: topical NSAID and asthma control—a possible oversight link. Respir Med. 2016;118:1–3. https://doi.org/10.1016/j.rmed.2016.07.004 .
doi: 10.1016/j.rmed.2016.07.004
pubmed: 27578463
Kempers S, DuBois J, Forman S, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results. J Drugs Dermatol. 2020;19(11):1093–100. https://doi.org/10.36849/JDD.2020.5576 .
doi: 10.36849/JDD.2020.5576
pubmed: 33196758
Clebak KT, Mendez-Miller M, Croad J. Cutaneous cryosurgery for common skin conditions. Am Fam Phys. 2020;101:399–406.
Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma—short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18:275–94. https://doi.org/10.1111/ddg.14048 .
doi: 10.1111/ddg.14048
pubmed: 32130773
Maire C, Vignion-Dewalle AS, Cartier H, et al. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol. 2020;34:165–7. https://doi.org/10.1111/jdv.16112 .
doi: 10.1111/jdv.16112
Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis. Int J Dermatol. 2020;59:677–84. https://doi.org/10.1111/ijd.14767 .
doi: 10.1111/ijd.14767
pubmed: 32012240
Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171:1164–71. https://doi.org/10.1111/bjd.13138 .
doi: 10.1111/bjd.13138
pubmed: 24861492
Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191–6. https://doi.org/10.1111/j.1524-4725.1997.tb00020.x .
doi: 10.1111/j.1524-4725.1997.tb00020.x
pubmed: 9145962
Esmann S, Jemec GB. Patients’ perceptions of topical treatments of actinic keratosis. J Dermatol Treat. 2014;25:375–9. https://doi.org/10.3109/09546634.2012.757285 .
doi: 10.3109/09546634.2012.757285
Erntoft S, Norlin J, Pollard C, Diepgen T. Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. Br J Dermatol. 2016;175(5):1094–6.
doi: 10.1111/bjd.14680
Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013;17(8):35–41. https://doi.org/10.2147/PPA.S47126.PMID:24379656;PMCID:PMC3872140 .
doi: 10.2147/PPA.S47126.PMID:24379656;PMCID:PMC3872140
Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(965):e1-12. https://doi.org/10.1016/j.jaad.2013.12.045 .
doi: 10.1016/j.jaad.2013.12.045
Bubna AK. Imiquimod—its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47(4):354–9. https://doi.org/10.4103/0253-7613.161249 .
doi: 10.4103/0253-7613.161249
pubmed: 26288465
pmcid: 4527053
Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13:166–9.
pubmed: 24509967
Emmerich VK, Cull D, Kelly KA, et al. Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness. J Dermatol Treat. 2021;2021:1–4. https://doi.org/10.1080/09546634.2021.1917758 .
doi: 10.1080/09546634.2021.1917758
Peris K, Calzavara-Pinton PG, Neri L, et al. Italian expert consensus for the management of actinic keratosis in immunocompetent patients. J Eur Acad Dermatol Venereol. 2016;30:1077–84. https://doi.org/10.1111/jdv.13648 .
doi: 10.1111/jdv.13648
pubmed: 27060910
Ezzedine K, Painchault C, Brignone M. Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome. J Mark Access Health Policy. 2020;8:1829884. https://doi.org/10.1080/20016689.2020.1829884 .
doi: 10.1080/20016689.2020.1829884
pubmed: 33133432
pmcid: 7580760
Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335–9.
pubmed: 12502122
Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70:22–9.
pubmed: 12353677
Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol. 2016;15:1218–24.
pubmed: 27741339
Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther Heidelb. 2017;7:81–96.
doi: 10.1007/s13555-016-0161-2
Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101–8. https://doi.org/10.1111/j.1365-2133.2011.10387.x .
doi: 10.1111/j.1365-2133.2011.10387.x
pubmed: 21517801
Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3:401–7.
pubmed: 15303784
Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415. https://doi.org/10.1002/14651858.CD004415.pub2 .
doi: 10.1002/14651858.CD004415.pub2
pubmed: 23235610
Nisticò S, Del-Duca E, Torchia V, et al. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. Int J Immunopathol Pharmacol. 2018;32:925. https://doi.org/10.1177/2058738418757925 .
doi: 10.1177/2058738418757925
Steeb T, Wessely A, Harlaß M, et al. A systematic review and meta-analysis of interventions for actinic keratosis from post-marketing surveillance trials. J Clin Med. 2020;9:2253. https://doi.org/10.3390/jcm9072253 .
doi: 10.3390/jcm9072253
pmcid: 7408895
Babino G, Diluvio L, Bianchi L, et al. Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. Curr Med Res Opin. 2016;32:1345–9. https://doi.org/10.1080/03007995.2016.1174678 .
doi: 10.1080/03007995.2016.1174678
pubmed: 27046744
Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384:512–20. https://doi.org/10.1056/NEJMoa2024040 .
doi: 10.1056/NEJMoa2024040
pubmed: 33567191
Markham A, Duggan S. Tirbanibulin: first approval. Drugs. 2021;81:509–13.
doi: 10.1007/s40265-021-01479-0
Noels EC, Hollestein LM, Van Egmond S, et al. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. Br J Dermatol. 2019;181:544–53. https://doi.org/10.1111/bjd.17632 .
doi: 10.1111/bjd.17632
pubmed: 30636037
pmcid: 6850060
Heppt MV, Steeb T, Ruzicka T, et al. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180:740–8. https://doi.org/10.1111/bjd.17435 .
doi: 10.1111/bjd.17435
pubmed: 30447074
Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994–9. https://doi.org/10.1111/j.1365-2133.2008.08488.x .
doi: 10.1111/j.1365-2133.2008.08488.x
pubmed: 18341663
Simon JC, Dominicus R, Karl L, et al. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29:881–9. https://doi.org/10.1111/jdv.12702 .
doi: 10.1111/jdv.12702
pubmed: 25257941
Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol. 2014;170:1114–21. https://doi.org/10.1111/bjd.12847 .
doi: 10.1111/bjd.12847
pubmed: 24472087
Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34–40. https://doi.org/10.1111/j.1365-2133.2007.08271.x .
doi: 10.1111/j.1365-2133.2007.08271.x
pubmed: 18067630
Berman B, Shabbir AQ, MacNeil T, et al. Variables in cryosurgery technique associated with clearance of actinic keratosis. Dermatol Surg. 2017;43:424–30. https://doi.org/10.1097/DSS.0000000000000989 .
doi: 10.1097/DSS.0000000000000989
pubmed: 28002105
Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687–92. https://doi.org/10.1111/j.1365-4632.2004.02056.x .
doi: 10.1111/j.1365-4632.2004.02056.x
pubmed: 15357755
De Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20–43. https://doi.org/10.1111/bjd.15107 .
doi: 10.1111/bjd.15107
pubmed: 28098380
Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26:728–32. https://doi.org/10.1046/j.1524-4725.2000.99197.x .
doi: 10.1046/j.1524-4725.2000.99197.x
pubmed: 10940057
Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J Drugs Dermatol. 2011;10:1049–56.
pubmed: 22052276
Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155:1262–9. https://doi.org/10.1111/j.1365-2133.2006.07520.x .
doi: 10.1111/j.1365-2133.2006.07520.x
pubmed: 17107399
Wiegell SR, Haedersdal M, Eriksen P, et al. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol. 2009;160:1308–14. https://doi.org/10.1111/j.1365-2133.2009.09119.x .
doi: 10.1111/j.1365-2133.2009.09119.x
pubmed: 19416257
Wiegell SR, Fabricius S, Heydenreich J, et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol. 2013;168:186–91. https://doi.org/10.1111/j.1365-2133.2012.11200.x .
doi: 10.1111/j.1365-2133.2012.11200.x
pubmed: 22860885
Lerche CM, Heerfordt IM, Heydenreich J, Wulf HC. Alternatives to outdoor daylight illumination for photodynamic therapy-use of greenhouses and artificial light sources. Int J Mol Sci. 2016;17(3):309. https://doi.org/10.3390/ijms17030309 .
doi: 10.3390/ijms17030309
pubmed: 26938525
pmcid: 4813172
O’Mahoney P, Haigh N, Wood K, et al. A novel light source with tuneable uniformity of light distribution for artificial daylight photodynamic therapy. Photodiagn Photodyn Ther. 2018;23:144–50. https://doi.org/10.1016/j.pdpdt.2018.06.013 .
doi: 10.1016/j.pdpdt.2018.06.013
Dattola A, Gutiérrez Garcìa-Rodrigo C, Tambone S, et al. 5-Aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an Italian study in the real-life setting. G Ital Dermatol Venereol. 2020;155:636–41. https://doi.org/10.23736/S0392-0488.20.06598-0 .
doi: 10.23736/S0392-0488.20.06598-0
pubmed: 33026214
Mordon S, Vignion-Dewalle AS, Abi-Rached H, et al. The conventional protocol vs a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. Br J Dermatol. 2020;182:76–84. https://doi.org/10.1111/bjd.18048 .
doi: 10.1111/bjd.18048
pubmed: 31021404
Algorri JF, Ochoa M, Roldán-Varona P, Rodríguez-Cobo L, López-Higuera JM, et al. Photodynamic therapy: a compendium of latest reviews. Cancers (Basel). 2021;13:4447. https://doi.org/10.3390/cancers13174447 .
doi: 10.3390/cancers13174447
Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176–81.
doi: 10.1001/archderm.1995.01690140060009
Steeb T, Koch EAT, Wessely A, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35:641–9. https://doi.org/10.1111/jdv.16844 .
doi: 10.1111/jdv.16844
pubmed: 32745330
Tai F, Shah M, Pon K, et al. Laser resurfacing monotherapy for the treatment of actinic keratosis. J Cutan Med Surg. 2021;2021:12034754211027516. https://doi.org/10.1177/12034754211027515 .
doi: 10.1177/12034754211027515
Lai M, Pampena R, Cornacchia L, et al. Treatments of actinic cheilitis: a systematic review of the literature. J Am Acad Dermatol. 2020;83:876–87. https://doi.org/10.1016/j.jaad.2019.07.106 .
doi: 10.1016/j.jaad.2019.07.106
pubmed: 31400450
Fleming P, Zhou S, Bobotsis R, et al. Comparison of the treatment guidelines for actinic keratosis: a critical appraisal and review. J Cutan Med Surg. 2017;21:408–17. https://doi.org/10.1177/1203475417708166 .
doi: 10.1177/1203475417708166
pubmed: 28510496
Heppt MV, Steeb T, Leiter U, et al. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:863–73. https://doi.org/10.1111/jdv.15459 .
doi: 10.1111/jdv.15459
pubmed: 30710390
Steeb T, Wessely A, Leiter U, et al. The more the better? An appraisal of combination therapies for actinic keratosis. J Eur Acad Dermatol Venereol. 2020;34:727–32. https://doi.org/10.1111/jdv.15998 .
doi: 10.1111/jdv.15998
pubmed: 31587385
Jambusaria-Pahlajani A, Ortman S, Schmults CD, et al. Sequential curettage, 5 fluorouracil, and photodynamic therapy for field cancerization of the scalp and face in solid organ transplant recipients. Dermatol Surg. 2016;42:S66–72. https://doi.org/10.1097/DSS.0000000000000589 .
doi: 10.1097/DSS.0000000000000589
pubmed: 26730976
Gholam P, Fink C, Bosselmann I, et al. Retrospective analysis evaluating the effect of a keratolytic and physical pretreatment with salicylic acid, urea and curettage on the efficacy and safety of photodynamic therapy of actinic keratoses with methylaminolaevulinate. J Eur Acad Dermatol Venereol. 2016;30:619–23. https://doi.org/10.1111/jdv.13449 .
doi: 10.1111/jdv.13449
pubmed: 26508040
Lambert SR, Mladkova N, Gulati A, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer. 2014;110:520–9. https://doi.org/10.1038/bjc.2013.760 .
doi: 10.1038/bjc.2013.760
pubmed: 24335922
Cramer P, Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020;25:49–58. https://doi.org/10.1080/14728214.2020.1730810 .
doi: 10.1080/14728214.2020.1730810
pubmed: 32067498
Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159:205–10. https://doi.org/10.1111/j.1365-2133.2008.08615.x .
doi: 10.1111/j.1365-2133.2008.08615.x
pubmed: 18476957
Stockfleth E, Hofbauer GFL, Reinhold U, et al. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol. 2019;180:297–305. https://doi.org/10.1111/bjd.17124 .
doi: 10.1111/bjd.17124
pubmed: 30171698
Rajaratnam R. Resiquimod for actinic keratosis: is this a new treatment option? Br J Dermatol. 2019;180:254–5. https://doi.org/10.1111/bjd.17436 .
doi: 10.1111/bjd.17436
pubmed: 30714105
Safety and Efficacy Study of AM001 cream in the treatment of actinic keratosis [Internet]. 2019. https://clinicaltrials.gov/ct2/show/NCT03210740 . Accessed 31 Dec 2019.
Pflugfelder A, Andonov E, Weide B, et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. Br J Dermatol. 2015;172:926–32. https://doi.org/10.1111/bjd.13342 .
doi: 10.1111/bjd.13342
pubmed: 25124939
Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):17–20. https://doi.org/10.1111/jdv.14091 .
doi: 10.1111/jdv.14091
pubmed: 28263022
Thorell K, Midlöv P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. BMC Geriatr. 2020;20(1):73. https://doi.org/10.1186/s12877-020-1476-5 .
doi: 10.1186/s12877-020-1476-5
pubmed: 32075586
pmcid: 7032002
Neri L, Peris K, Longo C, Actinic Keratosis—TReatment Adherence INitiative (AK-TRAIN) study group, et al. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019;33(1):93–107. https://doi.org/10.1111/jdv.15142 .
doi: 10.1111/jdv.15142
pubmed: 29920789